| Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti‐tumour activity CM Shipman, MJ Rogers, JF Apperley, RGG Russell, PI Croucher British journal of haematology 98 (3), 665-672, 1997 | 523 | 1997 |
| Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma PI Croucher, CM Shipman, J Lippitt, M Perry, K Asosingh, A Hijzen, ... Blood, The Journal of the American Society of Hematology 98 (13), 3534-3540, 2001 | 461 | 2001 |
| The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel SP Jagdev, RE Coleman, CM Shipman, A Rostami-H, PI Croucher British journal of cancer 84 (8), 1126-1134, 2001 | 461 | 2001 |
| The pharmacology of bisphosphonates and new insights into their mechanisms of action RGG Russell, MJ Rogers, JC Frith, SP Luckman, FP Coxon, HL Benford, ... Journal of Bone and Mineral Research 14 (S2), 53-65, 1999 | 394 | 1999 |
| Zoledronic acid treatment of 5T2MM‐bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and … PI Croucher, H De Raeve, MJ Perry, A Hijzen, CM Shipman, J Lippitt, ... Journal of Bone and Mineral Research 18 (3), 482-492, 2003 | 336 | 2003 |
| The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway CM Shipman, PI Croucher, R Graham, G Russell, MH Helfrich, MJ Rogers Cancer research 58 (23), 5294, 1998 | 324 | 1998 |
| Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human … CM Shipman, PI Croucher Cancer research 63 (5), 912, 2003 | 289 | 2003 |
| The pathogenesis of the bone disease of multiple myeloma CM Edwards, J Zhuang, GR Mundy Bone 42 (6), 1007-1013, 2008 | 235 | 2008 |
| Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma K Vanderkerken, E De Leenheer, C Shipman, K Asosingh, A Willems, ... Cancer research 63 (2), 287, 2003 | 231 | 2003 |
| Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo CM Edwards, JR Edwards, ST Lwin, J Esparza, BO Oyajobi, B McCluskey, ... Blood, The Journal of the American Society of Hematology 111 (5), 2833-2842, 2008 | 195 | 2008 |
| Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer SR Rao, AE Snaith, D Marino, X Cheng, ST Lwin, IR Orriss, FC Hamdy, ... British journal of cancer 116 (2), 227-236, 2017 | 179 | 2017 |
| Eph receptors and ephrin signaling pathways: a role in bone homeostasis CM Edwards, GR Mundy International journal of medical sciences 5 (5), 263, 2008 | 166 | 2008 |
| Role of osteoprotegerin (OPG) in cancer I Holen, CM Shipman Clinical science 110 (3), 279-291, 2006 | 155 | 2006 |
| A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease BP Ayati, CM Edwards, GF Webb, JP Wikswo Biology direct 5, 1-17, 2010 | 153 | 2010 |
| Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. JA Fowler, ST Lwin, MT Drake, JR Edwards, RA Kyle, GR Mundy, ... Blood, 2011 | 139 | 2011 |
| Osteoclasts in Multiple Myeloma Are Derived from Gr-1+ CD11b+ Myeloid-Derived Suppressor Cells J Zhuang, J Zhang, ST Lwin, JR Edwards, CM Edwards, GR Mundy, ... PloS one 7 (11), e48871, 2012 | 138 | 2012 |
| Metformin and prostate cancer: a new role for an old drug J Whitburn, CM Edwards, P Sooriakumaran Current urology reports 18, 1-7, 2017 | 125 | 2017 |
| LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis JR Edwards, SG Sun, R Locklin, CM Shipman, IE Adamopoulos, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2006 | 114 | 2006 |
| Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1 JA Fowler, GR Mundy, ST Lwin, CM Edwards Cancer Research, 2012 | 99 | 2012 |
| Contributions of the host microenvironment to cancer-induced bone disease SWZ Olechnowicz, CM Edwards Cancer research 74 (6), 1625-1631, 2014 | 98 | 2014 |
James EdwardsUniversity of OxfordGeverifieerd e-mailadres voor ndorms.ox.ac.uk